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INTRODUCTION
There is good evidence supporting the argument that 
endoscopic biliary drainage (EBD) is preferred to surgical 
bypass for biliary decompression in obstructive jaundice 
due to pancreatic cancer (1-3). This is not the case 
when it comes to choosing EBD or percutaneous biliary 
drainage (PBD) with or without stenting (PBDS) for relief 
of malignant biliary obstruction because few randomized, 
comparative studies exist. Differences in performance of 
EBD and PBD are even more clinically important now that 
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effective treatment for biliary cancers has become available. 
For example, successful surgical resection (R0) for Klatskin 
tumors has increased from 13% to 60% in a 15 year period 
(4); surgical resection of Klatskin tumors offers the best 
treatment results with a median 5 year survival of 30% to 
40% (5, 6). Equally important, advances in interventional 
radiology have enabled patients with to be upgraded 
unresectable Klatskin tumors on conventional grounds to 
resectable candidates. These patients have small future liver 
remnants which are stimulated to undergo compensatory 
hypertrophy with pre-operative portal vein embolization 
and biliary drainage (6). Even for patients with inoperable 
cholangiocarcinomas but eligible for chemotherapy, their 
median survival can be extended to 11.8 months with the 
combination of cisplatin and gemcitabine vs a period of 
less than 4.8 months in patients treated with gemcitabine 
alone (7). In short, satisfactory decompression of biliary 
obstruction is crucial for adequate symptomatic relief and 
for patients to benefit from modern treatment. How best to 
achieve this drainage has been, and continues to be, the 
primary concern for patients, physicians and other care-
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givers alike. 
Both endoscopic and percutaneous methods of biliary 
decompression offer relief for malignant biliary obstruction; 
each has its own performance characteristics depending on 
the obstruction sites. This article examines the published 
evidence in support of the best strategy in managing 
malignant biliary obstruction.
Search Strategy and Results
A literature search for all prospective randomized trials 
comparing endoscopic and percutaneous biliary drainage 
was made. Retrospective, non-randomized comparative 
studies from 2000 to 2010 were also included. We limited 
the review to publications in English and excluded earlier 
studies as technical improvements in recent years have 
rendered them irrelevant to current interventional practices. 
We acknowledge that our search may be incomplete with 
but believe that we have captured the most important 
evidence. 
We identified two prospective randomized controlled 
trials (RCTs) comparing the outcomes of endoscopic 
and percutaneous biliary stenting in malignant biliary 
obstruction arising at the hilar region and distal common 
bile duct. (8, 9) We found only one RCT comparing the 
two methods in patients with gallbladder cancer causing 
hilar obstruction (10) Since 2000, three retrospective non-
randomized comparative studies were published (11-13) - 
one on pre-operative biliary drainage (13) and the other 
2 on palliation of Klatskin tumors. (11, 12) One of the 
palliative studies compared metallic stent insertion by both 
methods. (12) The study design, inclusion and exclusion 
criteria, sites of obstruction and types of intervention are 
detailed in Table 1. The treatment outcomes including 
efficacy, complications, 30 day mortality, conversion from 
one intervention to the other, and patient survival are 
tabulated in Table 2.  
Drainage in Distal Bile Duct Obstruction
The 2 prospective randomized trials (8, 9) comparing 
EBD vs PBDS in hilar and distal biliary obstruction were 
published 15 years apart, and reflect the advances made 
in PBD and PBDS over this period. Although both were 
palliative studies, with similar inclusion and exclusion 
criteria, and similar endpoints, they differed in the type 
of stents inserted. In the first trial, plastic stents were 
used for both EBD and PBDS. However metallic stents 
were inserted percutaneously in the second trial and the 
results were compared with EBD using plastic stents. Both 
Table 1. Comparative Studies between EBD and Percutaneous Drainage in Malignant Biliary Obstruction: Study Type, 
Inclusion, Exclusion criteria, Obstruction Site
Study
Type & 
# Pts
Inclusion Criteria Exclusion Criteria Obstruction Site Intervention
Speer (8)
1987
RCT
N = 75
Palliative. Inoperable 
  pancreatic, bile duct, 
  GB cancers
Duodenal obstruction, 
  previous surgery, other 
  primary malignancy.
Mixed 
  (Hilar and distal)
EBD plastic vs 
  PBDS plastic
Pinol (9)
2002
RCT
N = 54
Palliative. Inoperable 
  Ca pancreas, bile 
  duct, metastatic 
  nodes ECOG < 2
Duodenal obstruction, 
  previous surgery, diffuse 
  tumoral infiltration liver, 
  ECOG > 2.
Mixed 
  (Hilar and distal)
EBD plastic stent vs 
  PBDS metallic stents
Saluja (10)
2008
RCT
N = 54
Palliative. Inoperable
  gallbladder carcinoma 
  with hilar obstruction
Duodenal obstruction, 
  resectable cancers, Bismuth 
  I/IV, Metal stents
Hilar 
  (Bismuth II or 
  III type) 
EBD plastic stent 
  vs PBD
Lee (11)
2007
Retro
N = 134
Palliative. Inoperable 
  Klatskin tumors
Gallbladder ca, metastatic 
  disease, previous resection 
  for Klatskin tumors
Hilar 
  (Bismuth II, III, IV)
External PBD vs 
  EBD with plastic stents 
  vs PBDS Metallic stent 
Paik (12)
2009
Retro
N = 85
Palliative. Advanced 
  Klatskin tumors.
Previous resection/ 
  chemotherapy or radiation
Hilar 
  (Bismuth III & IV)
EBD – metallic stents
  Per –metallic stents
Kloek (13)
2010
Retro
N = 101
Curative. Resectable
  Klatskin tumors
Non-resectable 
  Klatskin tumors
Hilar
EBD plastic stents 
  vs PBD 
Note.— RCT = randomized controlled trials, Retro = retrospective, non-randomized study, EBD = endoscopic biliary drainage 
(stenting), PBDS = percutaneous insertion of biliary stents, PBD = percutaneous biliary drainage with cathetersKorean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S58
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trials were stopped before reaching their full enrolment for 
ethical concerns but for different reasons. In the first RCT, 
the statistically higher 30 day mortality (33% vs 15%) and 
failure of drainage (61% vs 81%) in PBDS were the reasons. 
There was no significant difference in 30 day mortality 
between EBD and PBDS in the second trial, but significant 
differences existed in therapeutic success (71% vs 42%, 
p = 0.03) and median survival (3.7 months vs 2 months, 
p = 0.02), in favour of PBDS. As a result, each study drew 
a different conclusion. The first trial recommended that 
endoscopy should be tried first in the elderly and frail when 
stenting is being considered. The second trial concluded 
that metal stents inserted percutaneously are an alternative 
to endoscopic plastic stenting. Which one of these 
conclusions is more applicable in today’s practice and why?
Since the first trial in 1987 (8), major technical advances 
have taken place in endoscopy and Interventional Radiology 
resulting in improved performance in biliary drainage, 
especially for percutaneous work. Examples of these 
advances were the use of ultrasound guidance (14) and 
improved equipment, including the introduction of self-
expandable metallic stents (SEMS) (15). These advances 
have made PBD and stenting easier and safer to perform. 
Indeed, the high mortality in PBDS reported in the first 
trial has not been shown in any comparative series since 
1987. Instead, significant differences in the therapeutic 
success and survival benefits with PBDS were reported in 
the second published randomized trial. (9) The superior 
performance of metallic stents compared to plastic stents 
has also been reported in EBD (16, 17). The longer duration 
of metallic stent patency has reduced the need for future 
re-interventions and enhances cost effectiveness (18). 
More importantly, plastic stents have long been replaced 
by metallic stents in percutaneous practice even though 
they are still used for EBD. Consequently, the results and 
conclusion of the first randomized trial are no longer 
relevant in today’s clinical practice. By default, the second 
trial now becomes the only relevant source for level I 
evidence in biliary intervention and its recommendations 
remain valid today; percutaneous insertion of self-expanding 
metallic stents is an alternative to endoscopic stenting. 
The question that now remains is: how does endoscopic 
Table 2. Comparative Studies between EBD and Percutaneous Drainage in Malignant Biliary Obstruction: Efficacy, 
Complications and Outcomes
Study
Number of 
patients
Technical 
success
Therapeutic 
success (p value)
30-day 
Mortality
Complications Conversion Median Survival
Speer (8)
1987
EBD (39)
PBDS (36)
89%
76% 
NS
81%
61% 
(p = 0.007)
16%
33% 
p = 0.016
19%
67% N/A
To PBDS n = 3
To EBD n = 7
159 days
113 days NS
Pinol (9)
2002
EBD (26)
PBDS (28)
58%
75% 
NS
42%
71%
(p = 0.03)
42%
36%
NS
35%
61%
NS
To PBDS n = 6
To EBD n = 1
2 months
3.7 months 
p = 0.02
Saluja (10)
2008
EBD (27)  
PBD (27)
81 %
93% 
NS
41%
89% 
(p < 0.001)
4%            
8% 
NS
52%
18%
(p = 0.04)    
To PBD n = 2        
To EBD n = 0
75 days
53 days NS
Lee (11)
2007
Ext PBD (66)
EBD (34)
PBDS (34)
N/A 94%              
79.4%         
97.1%           
(0.03)
2.1%         
0%         
1.5%                           
 
19.7%
38.2%
50%
N/A N/A
Paik (12)
2009
EBD (44)
PBS (41)
N/A 77.3%
92% 
(p = 0.049)
1.2%
0% 
NS
29.5%
31.7% 
NS
N/A 6.2 months 
8.7 months
NS
Duration to 
success
Cholangitis
Kloek (13)
2010
EBD (90)
PBD (11)
81% 
100% 
NS
15 wk
11 wk 
(p = 0.033)
N/A 48%
9%
(p = 0.02)
To PBD 33% 
To EBD 0%
N/A
Note.— EBD = Endoscopic biliary drainage, Ext PBD = external Percutaneous biliary drainage, PBDS = Percutaneous biliary 
drainage with stent, PBD = Percutaneous biliary drainage with catheter, NS = Not statistically significant, N/A = not availableKorean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S59
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insertion of metallic stents compare with the percutaneous 
method? This question will remain unanswered until results 
of a randomized study become available, which is unlikely 
to appear soon. 
Biliary Drainage in Hilar Obstruction
Malignant obstruction at the hilar and peri-hilar regions 
is usually caused by Klatskin tumors or gallbladder 
carcinoma with local extension to involve the hilum. 
These obstructions present significant challenges for both 
endoscopic and percutaneous biliary drainage for a number 
of reasons. First and foremost, patients with Klatskin 
tumor or malignant hilar obstruction do not tolerate 
failure of drainage well, an observation recognized by both 
radiologists and endoscopists alike. Devierre (19) cautioned 
us of the serious negative impact on outcomes due to 
sepsis of undrained segments. Life-threatening septic 
complications may occur, and prolonged sepsis may delay 
or even disqualify patients from their intended treatment. 
Unlike distal biliary obstruction, remedial bypass surgery is 
seldom available and often risky. Second, biliary drainage 
is technically more difficult to perform, especially for EBD, 
and more than one stent or drainage catheter may be 
required due to the presence of multiple obstructed sites. 
Third, technical success may not translate into therapeutic 
success as consistently shown by all the RCT and 
retrospective studies in this review. Some general principles 
are available but they are not reliable predictors. Despite 
all of the above, some patients may benefit from well-
designed treatment strategies skilfully executed by teams of 
dedicated health professionals, with long-term survival. Very 
often, the optimal strategy begins by choosing a drainage 
method that is highly successful and safe. In the East and 
Japan, the method of choice is PBD (6), but in Europe and 
North America, EBD is preferred. (13, 20). Here we review 
RCTs and non-randomized retrospective studies for evidence 
to address this controversy.  
For hilar obstruction, the only randomized trial (10) 
showed that PBD out-performed EBD using plastic stents; a 
significantly higher therapeutic success (89% vs 41%, p ≤ 
0.001) and a significantly lower complication rate (52% vs 
18%, p = 0.04,) than EBD. This trial also assessed quality 
of life in the study groups and demonstrated a significant 
improvement in scores in the PBD group at 3 months post 
insertion.
The higher therapeutic success in PBD over EBD was also 
confirmed by 2 retrospective, non-randomized palliative 
studies (Lee (11) 97% vs 79%, p = 0.03; Paik (12): 92.7% vs 
77.3%, p = 0.049) and corroborated by a retrospective pre-
operative study. (13) It should be noted that metallic stents 
were inserted in both EBD and PBD for palliation in the 
Paik study. Paik (12) also showed a significant increase in 
survival in those with initial successful drainage compared 
with those who failed the first attempt but succeeded 
subsequently (8.7 months vs 1.8 months, p <0.001).  
In a retrospective non-randomized study in pre-operative 
drainage for Klatskin tumor, Kloek (13) reported that EBD 
took 15 weeks to achieve adequate therapeutic drainage 
while PBD took only 11 weeks (p = 0.033). In addition, 33% 
of patients in the EBD group were later converted to PBD 
due to inadequate or failed drainage. This report also found 
that PBD had fewer infectious complications and required 
fewer procedures. (13) Two other similar studies (20, 21) 
from tertiary referral centers in the United Kingdom also 
confirmed a high conversion rate from initial EBD to PBD 
from 80% (120 of 150 patients) to 88% (36 of 41 patients). 
None had reported a conversion in the opposite direction 
from failed PBD to EBD. The conclusions from these centres 
were uniformly negative towards EBD in pre-operative 
drainage in Klatskin tumors. 
In summary, we consistently found supportive evidence 
that favours PBD as the preferred drainage procedure 
in malignant hilar obstruction: higher therapeutic 
success, shorter time to reach desired drainage, and 
negligible conversion rate. With the emergence of newer 
chemotherapeutic agents, effective drainage is key to 
early treatment. In this regard, the method that allows 
chemotherapy or surgery to start earlier is more preferable. 
When patients fail to respond to their EBD and require 
conversion to PBD, treatment is delayed and or may even 
disqualify them (due to prolonged sepsis or its sequaele) 
from receiving the appropriate care that they require and 
deserve. In this respect, the method that has the highest 
rate of conversion from EBD to PBD 
is the least clinically desirable.
Reasons for Choosing EBD as the Preferred 
Drainage Procedure 
 
It is generally believed that EBD is less invasive and has 
fewer complications than percutaneous drainage. Other than 
the earliest RCT in 1987 (8), this has not been validated 
statistically in any comparative studies included in this Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S60
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review. In fact, in malignant hilar obstruction, one RCT (10) 
and one retrospective non-randomized study (13) reported 
a significantly higher rate of cholangitis in the EBD group 
compared with the percutaneous group.  
Cosmetic appeal is another reason for choosing EBD 
as the preferred drainage method as there is No need 
for catheter exposure as in PBD. Recent innovation in 
catheter fixation with the low profile device has improved 
the cosmetic appeal of PBD by making it less obtrusive. 
Once the device is applied, the external portion of the 
drainage catheter is shortened to 3 mm above the skin level 
and the device is taped to the skin with a small piece of 
adhesive over a small dressing. (Fig. 1) It also has an added 
benefit of allowing early detection of impending biliary re-
obstruction (22). When biliary re-obstruction occurs or is 
about to occur, bile leakage around the insertion site would 
appear, alerting the patient to seek medical help and thus 
avoiding severe sepsis that may otherwise follow. In EBD, 
signs of early stent occlusion are non-specific and are often 
missed or ignored by patients. When overt signs appear, 
severe sepsis may have already set in; vigorous antibiotic 
treatment or even hospitalization may become necessary. 
Both physicians and their patients should be aware of the 
trade-off between EBD and PBD when choosing the method 
for biliary drainage. 
Summary
In conclusion, the management of distal malignant 
biliary obstruction can be achieved most optimally 
through insertion of metallic stents either endoscopically 
or percutaneously. Evidence shows that metallic stents 
inserted percutaneously results in better outcomes than 
plastic stents inserted endoscopically. For malignant 
hilar obstruction, percutaneous drainage with catheter or 
metallic stents is preferred to endoscopic plastic stents or 
metallic stents.  
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